The role of TBK1 in cancer pathogenesis and anticancer immunity
The TANK-binding kinase 1 (TBK1) is a serine/threonine kinase belonging to the non-
canonical inhibitor of nuclear factor-κB (IκB) kinase (IKK) family. TBK1 can be activated by …
canonical inhibitor of nuclear factor-κB (IκB) kinase (IKK) family. TBK1 can be activated by …
Association of myelofibrosis phenotypes with clinical manifestations, molecular profiles, and treatments
HT Chifotides, S Verstovsek, P Bose - Cancers, 2023 - mdpi.com
Simple Summary Myelofibrosis is an aggressive bone marrow cancer whose clinical
presentation can be extremely heterogenous. Two distinct phenotypes, myeloproliferative …
presentation can be extremely heterogenous. Two distinct phenotypes, myeloproliferative …
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis
Janus kinase inhibitors (JAKi) approved for myelofibrosis provide spleen and symptom
improvements but do not address anemia, a negative prognostic factor. Momelotinib, an …
improvements but do not address anemia, a negative prognostic factor. Momelotinib, an …
[HTML][HTML] Anemia in myelofibrosis: current and emerging treatment options
F Passamonti, CN Harrison, RA Mesa… - Critical Reviews in …, 2022 - Elsevier
Myelofibrosis (MF) is a clonal hematologic malignancy with progressive bone marrow
fibrosis. Clinical manifestations of MF include splenomegaly, constitutional symptoms, and …
fibrosis. Clinical manifestations of MF include splenomegaly, constitutional symptoms, and …
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single‐arm, open‐label, phase 2, multicenter …
Y Zhang, H Zhou, M Duan, S Gao, G He… - American Journal of …, 2023 - Wiley Online Library
Although ruxolitinib improves splenomegaly and constitutional symptoms in patients with
myelofibrosis (MF), a substantial proportion of patients discontinue ruxolitinib because of …
myelofibrosis (MF), a substantial proportion of patients discontinue ruxolitinib because of …
MPN-478 MOMENTUM: phase 3 randomized study of Momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously …
R Mesa, A Gerds, A Vannucchi, HK Al-Ali… - … Myeloma and Leukemia, 2022 - Elsevier
Background: MMB, a JAK1/2 and ACVR1/ALK2 inhibitor, showed clinical activity in the MF
SIMPLIFY trials. The pivotal phase 3 MOMENTUM study of MF patients previously treated …
SIMPLIFY trials. The pivotal phase 3 MOMENTUM study of MF patients previously treated …
Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives
GG Loscocco, AM Vannucchi - International Journal of Hematology, 2022 - Springer
Classic Philadelphia-negative myeloproliferative neoplasms (MPN) include polycythemia
vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), classified as primary …
vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), classified as primary …
Momelotinib: first approval
SJ Keam - Drugs, 2023 - Springer
Momelotinib (OJJAARA) is an oral Janus kinase 1 and 2 (JAK1/JAK2) and activin A receptor,
type I (ACVR1) inhibitor that has been developed for the treatment of myelofibrosis (MF). In …
type I (ACVR1) inhibitor that has been developed for the treatment of myelofibrosis (MF). In …
Underpinning IL-6 biology and emphasizing selective JAK blockade as the potential alternate therapeutic intervention for rheumatoid arthritis
S Srivastava, M Rasool - Life Sciences, 2022 - Elsevier
Abstract Interleukin 6 (IL-6), a pleiotropic inflammatory cytokine, is produced transiently due
to tissue damage and infections. Nonetheless, IL-6 contributes to the host regenerative …
to tissue damage and infections. Nonetheless, IL-6 contributes to the host regenerative …
Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of …
N Polverelli, JC Hernández-Boluda, T Czerw… - The Lancet …, 2023 - thelancet.com
Splenomegaly is a hallmark of myelofibrosis, a debilitating haematological malignancy for
which the only curative option is allogeneic haematopoietic cell transplantation (HCT) …
which the only curative option is allogeneic haematopoietic cell transplantation (HCT) …